Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia

V. Liso, G. Speechia, S. Capalho, V. Pavone, A. Iacobazzi, M. L. Iaculli, R. Dione, N. Pansini

Research output: Contribution to journalArticle

Abstract

Twenty adult patients with relapsed or refractory acute lymphoblastic leukemias (ALL) received a regimen employing two courses of mitoxantrone 12 mg/m2 by rapid intravenous infusion on days 1, 2 and 3 and cytosine arabinoside (ARA-C) 200 mg/m2/day by continuous infusion on days 1–7. Complete remission (CR) was achieved in 10 of 20 (50%) patients (3 refractory and 7 relapsed). Median duration of CR was 5 months (range 2–9). The treatment was associated with minimal extrahematologic toxicity, with no cardiac toxicity. Our results are nearly in line with therapeutic responses obtained with regimens employing megadose therapy (HD ARA-C). Because of acceptable toxicity, mitoxantrone plus continuous infusion of a standard dose of ARA-C could be considered for relapsed of refractory ALL patients eligible for an intensive therapeutic approach (bone marrow transplantation) after a second CR.

Original languageEnglish
Pages (from-to)54-57
Number of pages4
JournalActa Haematologica
Volume87
Issue number1-2
DOIs
Publication statusPublished - 1992

Keywords

  • Acute lymphoblastic leukemia
  • Continuous Infusion
  • Cytosine arabinoside
  • Mitoxantrone

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this